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Background: Electrical storm (ES) is a life threatening emergency. There is little data avail-
able regarding acute outcome of ES.
Aims: The study aimed to analyze the acute outcome of ES, various treatment modalities
used, and the factors associated with mortality.
Methods: This is a retrospective observational study involving patients admitted with ES at
our centre between 1/1/2007 and 31/12/2013.
Results: 41 patients (mean age 54.61 ± 12.41 years; 86.7% males; mean ejection fraction (EF)
44.51 ± 16.48%) underwent treatment for ES. Hypokalemia (14.63%) and acute coronary
syndrome (ACS) (14.63%) were the commonest identifiable triggers. Only 9 (21.95%) patients
already had an ICD implanted. Apart from antiarrhythmic drugs (100%), deep sedation
(87.8%), mechanical ventilation (24.39%) and neuraxial modulation using left sympathetic
cardiac denervation (21.95%) were the common treatment modalities used. Thirty-three
(80.49%) patients could be discharged after a mean duration of 14.2 ± 2.31 days. Eight
(19.5%) patients died in hospital. The mortality was significantly higher in those with
EF < 35% compared to those with a higher EF (8 (42.11% vs 0 (0%), p ¼ 0.03)). There was no
significant difference in mortality between those with versus without a structural heart
disease (8 (21.1% vs 0 (0%), p ¼ 0.32)). Comparison of mortality an ACS with ES versus ES of
other aetiologies (3 (50%) vs 5 (14.29) %, p ¼ 0.076)) showed a trend towards significance.
Conclusion: With comprehensive treatment, there is reasonable acute survival rate of ES.
Hypokalemia and ACS are the commonest triggers of ES. Patients with low EF and ACS have
higher mortality.
Copyright © 2016, Indian Heart Rhythm Society. Production and hosting by Elsevier B.V.
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Acute Electrical storm (ES) is a life threatening emergency and
carries a significant risk of mortality. There is little data
regarding acute outcome of ES [1], especially from the devel-
oping world. Similarly, less is known on ES occurring in pa-
tients who have not undergone an implantable cardioverter
defibrillator (ICD) placement, since most of the studies per-
taining to ES are confined to patients with ICDs [2e4]. The
present study is a single center experience of treating patients
with acute ES irrespective of ICD implantation, focusing on
the treatment modalities used, outcome and the factors
associated with mortality.Objectives
Primary aim of the study was to analyze the acute outcome of
ES, whereas the secondary aim was to analyze the various
treatment modalities used, and the factors associated with
increased mortality.Methods
This is a retrospective observational study involving patients
with Electrical storm, between 1/1/2007 and 31/12/2013, at
Sree Chitra Tirunal Institute for Medical sciences and Tech-
nology (SCTIMST). The demographic parameters, the treat-
ment modalities used, and the acute outcome were analyzed.
Subjects were retrospectively recruited based on the Hospital
Medical records. The electrocardiogram (ECG) and/or ICD-
electrograms (EGMs) (for patients with ICD) were used to
diagnosis and delineate the details of the ventricular
arrhythmia (VA). Whenever ICD-EGMs were used rate,
morphology, stability, onset and AV dissociation were used to
discriminate VT from supraventricular arrhythmias. All pa-
tients whowere admitted for treatment of ES were included in
the study. Those with ES occurring within 1 week of ICD im-
plantation were excluded as ES is known to be triggered dur-
ing this period. Patients were also excluded if the available
data was incomplete.Definitions
Electrical storm (ES)
Recurrent ventricular arrhythmias (VA) in a short time (3
separate episodes in 24 hrs, each requiring termination by
intervention) or frequent defibrillator therapies (3 separate
discrete episodes of VAs, separated by more than 5 min in
24 hrs) or incessant VA (continuous VA that recurred promptly
despite intervention for termination over 12 hrs) [4,5].
Cessation of ES
ES was considered to be ceased after at least a 7 day-period
free of recurrent VAs.Ventricular tachycardia (VT)
VT was diagnosed by the standard ECG when available. When
Electrocardiographic (ECG) record of the VA could be obtained,
VF and polymorphic VT were diagnosed based on QRS mor-
phologies. When electrograms from ICDs (EGMs) alone were
available, VAs with <30 ms cycle length (CL) variation were
considered monomorphic, while those with CL variation
>30 ms were regarded as polymorphic [6].
Ventricular fibrillation (VF)
Electrocardiographic documentation of VF, or any VA of rate
>250/min with varying cycle length when ICD electrograms
alone were available.
Structural heart disease (SHD)
Was defined, for the purpose of this study, as diseases with
echocardiographically detectable abnormality.Statistical analysis
All the quantitative data are reported as mean ± S.D. Quali-
tative data are expressed as proportions. All the analyseswere
done using the SPSS 16 software. Fischer exact test was used
for comparison of categorical data.Results
The baseline parameters of the patients are shown in Table 1
The mean age was 54.61 ± 12.41 years and 31 (86.7%) were
males. Themean ejection fraction (EF) was 44.51± 16.48%. The
aetiological distribution of the patients is shown in Fig. 1.
Coronary artery disease was the commonest underlying dis-
ease. The mean number of VAs per ES episode was
11.15 ± 15.48 and the mean rate of VA during ES was
179.46 ± 69.46. The morphology of VA during the ES was RBBB
18 (43.9%), LBBB 12 (29.27%), Polymorphic/VF 8 (19.51%), ICD
EGM alone in 3 (7.31%). Though a clear triggering factor could
not be identified in the majority (60.97%), Hypokalemia
(14.63%) and acute coronary syndrome (ACS) (14.63%)
remained the commonest identifiable triggers that precipi-
tated an ES. The mean potassium level was 2.8 ± 0.22 mEq/dL
in those having hypokalemia. In a patient with Brugada syn-
drome, fever precipitated the ES and he was treated with
paracetamol, tepid sponging and Isoprenaline infusion. Only 9
(21.95%) patients had an ICD implanted before the occurrence
of ES. The appropriate ICD intervention during the ES was
shock alone in 3 (33.3%), and Anti Tachycardia Pacing (ATP)
with Shock in 6 (66.6%) of the patients.
Modalities used in treating ES (Table 2)
The various treatment modalities used in the management of
ES are shown in Table 2. Apart from antiarrhythmic drugs
which were invariably used, 36 (87.8%) patients underwent
deep sedation and 10 (24.39%) underwent mechanical
Table 1 e Parameters of the ES cohort (N ¼ 36).
Parameter Frequency
Age (Years) 54.61 ± 12.41
Sex Males 35 (85.36%)
Females 6 (14.64%)
EF (%) 44.51 ± 16.48
SHD 38 (92.68%)
Severe LV dysfunction (EF<35%) 27 (65.85%)
Type of VA during ES
Monomorphic VT 33 (80.49%)
Polymorphic VT 2 (4.88%)
VF 6 (14.63%)
No. of VA episodes per ES 14.25 ± 10.48
Triggers of ES
ACS 6 (14.63%)
Hypokalemia 6 (14.63%)
Worsening HF 3 (7.51%)
Fever 1 (2.31%)
None identified 25 (60.97%)
Patients already having an ICD 9 (21.95%)
ICD intervention (in patients already on
ICD)
Shock alone 3 (33.3%)
ATP þ Shock 6 (66.6%)
Mean No. of VA episodes 14.25 ± 10.48
Rate during ES (per minute) 192.46 ± 58.41
RFA in acute setting 1 (2.43%)
Acute Outcome Survival 33 (80.49%)
Mortality 8 (19.51%)
EF-Ejection fraction, ES-Electrical storm, ICD-Implantable car-
dioverter Defibrillator, RFA-Radiofrequency ablation, SHD- Struc-
tural heart disease, VT-Ventricular tachycardia, VA Ventricular
arrhythmia.
Fig. 1 e Shows the aetiological distribution of the patients.
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or bilateral stellate ganglion blockade or surgical left sympa-
thetic cardiac denervation was performed in 9 (21.95%) pa-
tients. Five of these patients had pharmacological left stellate
ganglion blockade initially, and later underwent surgical or
thoracoscopy guided left sympathetic cardiac denervation
(LSCD). One of these cases has been reported previously, and
the technical details explained [7]. This was effective in acutecontrol of ES in 7 (77.78%) patients. Only one patient (2.78%)
underwent RFA in the setting of ES and RFA could control ES in
this patient. Metoprolol followed by Amiodarone were the
commonest drugs to be used. Amiodarone was not used in
two patients who had previous history of thyrotoxicosis
related to Amiodarone intake. Sotalol was used in them.
Isoprenaline infusion proved to be useful in a patient with
Brugada syndrome whereas Diltiazem was used in a patient
with idiopathic short coupled torsades. Mexiletine was used
as a first line drug in a patient with long QT syndrome (LQTS-
3), and also in four other patients as an add-on medication
after parenteral Lidocaine was stopped. Temporary pacing to
shorten the heart rate was used in three patients. In patients
in whom an ICD was implanted, reprogramming of the device
was carried out to switch off the delivery of shocks and pro-
mote anti-tachycardia pacing (ATP).Acute outcome
Thirty-three (80.49%) patients could be discharged from the
hospital after successfully controlling ES, after a mean dura-
tion of 14.2 ± 2.31 days. Eight (19.5%) patients died in hospital.
Three of these mortalities were related to ES occurring in the
background of acute coronary syndrome (ACS). All of them
underwent adequate revascularisation. One of them died of
refractory ventricular fibrillation (VF), whereas worsening
heart failure and cardiogenic shock, with superimposed ven-
tricular arrhythmia episodes caused death in the other two.
Three had ischemic cardiomyopathy and dilated cardiomy-opathy was the substrate in two; all with severe LV dysfunc-
tion. Two of these deaths were due to worsening hypotension,
refractory heart failure culminating in electromechanical
dissociation/asystolic arrest. The mortality was significantly
higher in those with EF<35% compared to those with a higher
EF (8 (42.11% vs 0 (0%), p ¼ 0.03)). However, there was no sig-
nificant difference in mortality between those with versus
without a structural heart disease (8 (21.1% vs 0 (0%), p¼ 0.32)).
Table 2 e Various treatment modalities and antiarrhythmic drugs used in the acute treatment of ES.
Modality N (%) Drugs used N (%)
Antiarrhythmic drugs 41 (100%) Beta Blockers 39 (95.12%)
Deep Sedation 36 (87.8%) Parenteral Amiodarone 35 (85.36%)
Ventilation 10 (24.39%) Lignocaine 10 (24.39%)
ICD programming 9 (21.95%) Mexiletine 5 (12.2%)
Neuraxial modulation 9 (21.95%) Sotalol 2 (4.87%)
RFA 1 (2.4%) Verapamil 1 (2.4%)
ICD-Implantable cardioverter Defibrillator, RFA-Radiofrequency ablation.
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ACS versus ES of other aetiologies (3 (50%) vs 5 (14.29) %,
p ¼ 0.076) showed a trend towards significance.Discussion
The present study has a few unique features. Firstly, the acute
outcome of ES has not been studied so far, especially in pa-
tients without an ICD. Secondly, only patients needing inpa-
tient treatments for ES were included in the present study.
Thirdly, and more strikingly, the use of radiofrequency abla-
tion in the acute setting of ES was very less. The present study
thus represents the real-life scenario in much of the devel-
oping world where most patients do not afford an ICD, and
sophisticated modalities like electroanatomical mapping are
not available round-the clock even in tertiary care centres.
Similar to most other studies on ES, males were predomi-
nant in the present study as well [3,8]. There was no clear
trigger for ES in the majority. However, it is important to note
that acute coronary syndrome and hypokalemia were the
most common triggers identifiable. This is important because
both are amenable to treatment. Hypokalemia is common in
patients with heart failure or LV dysfunction, due to diuretic
use, and hence frequent monitoring of potassium levels and
meticulous correction of hypokalemia when present can
potentially prevent an ES event.
Only 19.51% of the patients in the ES group had VF/Poly-
morphic VT as the causative arrhythmia. The incidence of VF
as the causative arrhythmia, and the definition for classifying
VA as VF varies among various studies. The incidence was
comparable to that in many other studies [3,9]. A large pro-
portion of our patients (63.9%) had coronary artery disease
(CAD). Thus scar tissue was as the possible substrate of VA in
these patients. This may also explain the lower incidence of
VF in our patients, as scar tissue is more likely to have mul-
tiple potential re-entrant circuits, and likely to sustain
monomorphic VT.
The use of radiofrequency ablation
The use of RFA in the acute setting was extremely low in the
present study. There is variable evidence regarding the benefit
of RFA in the setting of ES. Izquierdo et al. [10] in their study,
have reported a 38% recurrence of ES after a single RFA pro-
cedure in patients with ES. However, in a larger study Car-
bucicchio et al. [11] reported a 92% ES free survival at 22
months. However in this series, multiple sessions of RFAwereperformed if needed and endpoint of non-inducibility of VT
after ablation was used. The proportion of patients on beta
adrenergic receptor blockers and Amiodarone in our study
was higher than that in other studies [2,3,6,9,12].
Outcome
There is no available data regarding acute outcome of ES. In
the present study there was a reasonable survival of 80.49%.
Themortality was higher in patients with EF < 35%, and when
ACS was the aetiology of ES. Another notable feature was that
worsening heart failure and cardiogenic shock, and not the
arrhythmic event itself, was the final cause of death in a sig-
nificant majority. This is concordant with the finding of
Mitchell et al who noted that electromechanical dissociation
accounted for a significant proportion of sudden deaths in
patients who had undergone an ICD implantation [13].Conclusions
The acute mortality of ES can be high. A comprehensive
management strategy can result in reasonable acute survival
in patients. Neuraxial modulation with left sympathetic car-
diac denervation is a promising strategy in this regard. Hy-
pokalemia and ACS are the commonest triggers of ES. This is
particularly of importance in resource limited background in
developing nations, where use of ICD and RFA is still very low.
Worsening heart failure and cardiogenic shock are important
mechanisms of mortality apart from the arrhythmia itself.
Patients with severe LV dysfunction and ACS have signifi-
cantly higher mortality due to ES.
Clinical implications
Close monitoring of patients with heart failure or LV
dysfunction to detect and correct hypokalemia may help in
preventing ES. Neuraxial modulation with LSCD is a useful
strategy that can be used when more sophisticated tech-
niques are not readily available. Severe LV dysfunction and
ACS may be simple clinical markers to identify patients at
especially high risk of mortality.
Limitations
The retrospective design of the study has its inherent limita-
tions. Most of the published studies on ES are of retrospective
design. The study population was heterogeneous regarding
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and thus the conclusions may not be uniformly applicable to
all patients alike.Source of funding
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